Cantor Fitzgerald analyst Pete Stavropoulos upgraded Alector (ALEC) to Overweight from Neutral. The Alector Brain Carrier platform positions Alector to become a major player in the neurodegenerative space for drugs that leverage blood-brain barrier-crossing technology to enhance delivery to the brain, the analyst tells investors in a research note. The ABC platform has significant potential value, which is underappreciated at current levels, the firm says.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC:
- Alector files $400M mixed securities shelf
- BTIG upgrades Alector to Buy on shift to novel therapeutics
- Alector upgraded to Buy from Neutral at BTIG
- Buy Rating on Alector: Strategic Pivot to Blood–Brain-Barrier Platform and Emerging Alzheimer’s Assets AL137 and AL064 Underpins Attractive Risk–Reward
- Alector: Holding Amid Pipeline Setback as ABC Brain Delivery Platform Awaits Clinical Validation